Mutations in CDKN1B have been discovered and confirmed to be most significantly altered in luminal breast cancer, a subtype that accounts for more than 60% of all breast cancers, and high CDKN1B expression has been demonstrated to predict sensitivity to endocrine therapy and chemotherapy in luminal breast cancer patients [9,10]. This evidence concerns the gene CDKN1B and breast carcinoma.